Food News and Research

RSS

Prenatal exposure to microbes may help protect child from developing allergies later in life

A pregnant woman's exposure to microbes may protect her child from developing allergies later in life. Researchers in Marburg, Germany find that exposure to environmental bacteria triggers a mild inflammatory response in pregnant mice that renders their offspring resistant to allergies.

8 Dec 2009

Marketers and retailers refrained from promoting any dietary supplement for H1N1 treatment

The trade associations of the dietary supplement industry today reaffirmed the industry's support for the responsible sale and use of health-promoting vitamins, minerals, herbs and other dietary supplements.

8 Dec 2009

Antiepileptic drugs may have a possible protective effect against seizure disorders

Despite government warnings about an increased risk of suicidal thoughts and actions while taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in individuals with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

People who drink may want to know that coffee won't sober them up, according to new laboratory research. Instead, a cup of coffee may make it harder for people to realize they're drunk.

8 Dec 2009

RCT licensee Dyax receives approval from the FDA for KALBITOR

RCT licensee Dyax Corp. has received approval from the U.S. Food and Drug Administration for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

7 Dec 2009

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

7 Dec 2009

Gloucester Pharmaceuticals to be acquired by Celgene

Celgene Corporation and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which Celgene Corporation will acquire Gloucester Pharmaceuticals. Celgene says the acquisition will continue to advance its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers.

7 Dec 2009

FDA approves two New Drug Applications

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved its first two New Drug Applications (NDAs) based on its proprietary OralXR+(TM) platform technology including the first-ever 24 hour liquid sustained release product.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

7 Dec 2009

Scientists identify aggression-promoting pheromone in flies’ antenna

Have you ever found yourself struggling to get your order taken at a crowded bar or lunch counter, only to walk away in disgust as more aggressive customers elbow their way to the front? It turns out that flies do much the same thing, according to biologists from the California Institute of Technology (Caltech).

7 Dec 2009

DBS therapy offers hope for epilepsy patients

Long-term data from an investigational study of Deep Brain Stimulation (DBS) Therapy for Epilepsy was released this week by Medtronic, Inc. (NYSE:MDT) at the American Epilepsy Society Meeting (AES) in Boston.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Vitamin D supplements may aid in treating cancer

The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer, says Dr. Drake.

7 Dec 2009

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.

7 Dec 2009

Norovirus-related illnesses linked to eating oysters, reveals report

The U.S. Food and Drug Administration is advising consumers to avoid eating oysters harvested from the San Antonio Bay on or after Nov. 16 due to reports of norovirus-associated illnesses in some people who had consumed oysters harvested from this area, which is located on the Gulf of Texas.

7 Dec 2009

Study explains how circadian rhythms can drive feeding and metabolism behaviors

One of the pioneers in research on sleep:wake circadian genes, Amita Sehgal, Ph.D., has discovered that fruit flies' appetite and consumption are controlled by two rival sets of clocks, one in neurons and the other in the fly fat body, which is analogous to the liver.

6 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Food News and Research

Prenatal exposure to microbes may help protect child from developing allergies later in life

Marketers and retailers refrained from promoting any dietary supplement for H1N1 treatment

Antiepileptic drugs may have a possible protective effect against seizure disorders

Social isolation and stress can raise breast cancer risk

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

RCT licensee Dyax receives approval from the FDA for KALBITOR

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Gloucester Pharmaceuticals to be acquired by Celgene

FDA approves two New Drug Applications

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

Scientists identify aggression-promoting pheromone in flies’ antenna

DBS therapy offers hope for epilepsy patients

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New approach to protein misfolding may lead to novel therapies for a number of diseases

Vitamin D supplements may aid in treating cancer

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

Norovirus-related illnesses linked to eating oysters, reveals report

Study explains how circadian rhythms can drive feeding and metabolism behaviors

Positive final data from Phase 2 study of ISTODAX presented

The future is bioengineered: Synthetic biology and global sustainability eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News